Troponina elevada en pacientes sin síndrome coronario agudo / Troponin Elevation in patients without acute coronary syndrome

RESUMEN

Introducción y objetivos: Las troponinas son biomarcadores específicos de daño miocárdico y tienen implicación en el diagnóstico y el pronóstico de pacientes con síndrome coronario agudo. El objetivo es determinar las características clínicas y el pronóstico en pacientes con elevación de troponina no diagnosticados de síndrome coronario agudo. Métodos: Se estudió retrospectivamente a 1.032 pacientes con determinación de troponinas en un servicio de urgencias, que quedaron distribuidos en tres grupos 681 pacientes sin elevación de troponina y sin síndrome coronario agudo, 139 con síndrome coronario agudo y 212 con troponina elevada sin diagnóstico de síndrome coronario agudo. Se compararon las características clínicas de estos tres grupos y su mortalidad hospitalaria y a los 12 meses de seguimiento. Conclusiones: La troponina elevada es un importante predictor de mortalidad, independientemente del diagnóstico definitivo del paciente (AU)

ABSTRACT

Introduction and objectives: Troponins are specific biomarkers of myocardial injury and are implicated in the diagnosis and prognosis of patients with acute coronary syndrome. Our purpose was to determine the clinical characteristics and prognosis of patients with troponin elevation who are not diagnosed with acute coronary syndrome. Methods: A total of 1032 patients with an emergency room troponin measurement were studied retrospectively, dividing them into 3 groups 681 patients with no troponin elevation and without acute coronary syndrome, 139 with acute coronary syndrome, and 212 with troponin elevation and not diagnosed with acute coronary syndrome. The clinical characteristics and in-hospital and 12-month mortality of these 3 groups were compared. Results: Patients with troponin elevation not diagnosed with acute coronary syndrome were older and had greater comorbidity than patients with acute coronary syndrome or no troponin elevation. The 12-month mortality was 30.2%, compared with 15.1% and 4.7% in the other groups (log rank test, P < .001). In the Cox logistic regression model adjusted for confounding variables, patients with troponin elevation and no diagnosis of acute coronary syndrome had higher mortality compared with patients with negative troponin without acute coronary syndrome (hazard ratio = 3.99; 95% confidence interval, 2.36-6.75; P < .001) and similar prognosis as patients with acute coronary syndrome. Conclusions: Troponin elevation is an important predictor of mortality, regardless of the patient's final diagnosis (AU)